Psomagen: Q1 2026 Revenue Up 12.4%, Operating Loss Down 61.3% — Continued Deficit Reduction

Consolidated Q1 2026 revenue: USD 8,755,533 (+12.4% YoY); operating loss: USD 487,025 (vs. -1,258,433, -61.3%); net loss attributable: USD 243,771 (vs. -1,206,196, -79.8%)
North America WGS market share rose from 2% to 6%; secured large government contracts: NIH Alzheimer's (up to USD 7.5M) and Michael J. Fox Foundation Parkinson's (up to USD 7M)
Expansion into new businesses (single-cell, proteomics, long-read sequencing) accelerating multi-omics foundry transition
Accumulated deficit: USD 62.49M; no dividends or share buyback/cancellation
Short-term borrowings: USD 2.85M (from parent Macrogen and affiliates); operating cash flow: USD 0.20M (slightly positive)